<DOC>
	<DOCNO>NCT02703961</DOCNO>
	<brief_summary>The standard treatment local advance cervical cancer concurrent chemoradiotherapy . The 3 year disease free survival 50-70 % . The distant metastasis main cause failure local advance cervical cancer treat 3-dimensional conformal radiotherapy ( 3D-CRT ) intensity modulate radiotherapy ( IMRT ) . The purpose study investigate efficacy tolerance concurrent adjuvant chemotherapy cisplatin docetaxel local advance cervical cancer . It expect 3 year disease free survival would increase 10 % new treatment schedule .</brief_summary>
	<brief_title>Randomized Control Trial Efficacy Safety Concurrent Adjuvant Chemotherapy Cervical Cancer</brief_title>
	<detailed_description>The cervical cancer common malignant gynecological tumor develop area . From 1999 , concurrent chemoradiotherapy establish standard treatment local advance cervical cancer . The modern radiotherapy technique , 3 dimensional conformal radiotherapy ( 3D-CRT ) , intensity modulate radiotherapy ( IMRT ) , image guide 3-dimensional brachytherapy ( 3D-BT ) , widely use treatment cervical cancer . The recently clinical outcome show 3 year local regional control 90 % ［1-3］ . The distant metastasis prove main cause failure death , especially patient pelvic lymph node metastasis , large volume tumor advance FIGO stage . data show 3 year distant metastasis free survival overall survival 64.7 % 64.6 % respectively patient huge pelvic lymph node metastasis FIGO stage III- IVA . The system treatment point distant metastasis become topic clinical investigation . Dueñas-González A ` ［4］ study demonstrate 3 year progress free survival distant metastasis free survival increase 8.9 % 8.3 % radial radiotherapy combine concurrent chemotherapy weekly gemcitabine cisplatin adjuvant chemotherapy triweekly gemcitabine cisplatin . Ryu SY［5］ also report triweekly concurrent cisplatin 3 cycle improve survival outcome compare weekly concurrent cisplatin . Retrospective study Tang Jelavić-TB［6-7］ suggest adjubant chemotherapy CCRT good DMFS OS . The aim present study prospectively investigate efficacy safety concurrent adjuvant chemotherapy cisplatin docetaxel patient local advanced cervical cancer , especially FIGO III-IVA without pelvic lymph node metastasis FIGO IB2-IIB pelvic lymph node metastasis .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Biopsyproven , invasive squamous cell carcinoma , adenocarcinoma , adenosquamouscarcinoma cervix 2 . FIGO clinical stage IB2IIB pelvic lymph node metastasis FIGO clinical stage IIIIVA without pelvic lymph node metastasis 3 . ECOG performance score 01 4 . The bone marrow , hepatic renal function normal registration 5 . The patient sign informed consent 1. clear cell small cell neuroendocrine , sarcoma 2 . FIGO stage IVB 3 . Prior invasive malignancy 4 . Prior systemic chemotherapy 5 . Prior radiotherapy pelvis abdomen 6 . Severe , active comorbidity 7 . Women pregnant 8. immunocompromised status</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>CCRT</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>cisplatin docetaxel</keyword>
</DOC>